Pfizer Acquires Stem-Cell Therapy From Athersys

pfizer stem cells

Pharmaceutical giant Pfizer recently announced that it was buying the rights to a controversial cell therapy from Athersys, a biotech company. This is all part of the corporations plan to become more involved in the ever-growing interest in stem cell therapies and research.

The acquisition will give Pfizer rights to develop Athersys’s cells to treat inflammatory bowel disease. It will pay Athersys $6 million initially and up to $105 million in the future.

The relatively small payment reflects that “it’s really early for cell therapy and there’s more research to be done,” said Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, a unit created by the company about 18 months ago to develop treatments based on stem cells.

Related Posts with Thumbnails

Leave a Reply

Contact Us

Tips, Leads, Suggestions, Just Want to Say Hello? Email Dan or Sarah at support (at) stemcellumbilicalcordblood (dot) com